Nexalin Technology, Inc. (NXL)

Market Cap	16.72M
Revenue (ttm)	131,065
Net Income (ttm)	-8.55M
Shares Out	17.42M
EPS (ttm)	-0.80
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33,824
Open	0.9600
Previous Close	0.9800
Day's Range	0.9539 - 1.0300
52-Week Range	0.5910 - 4.4900
Beta	4.05
Analysts	Strong Buy
Price Target	5.00 (+420.78%)
Earnings Date	Aug 7, 2025

About NXL

Nexalin Technology, Inc. designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy. It also offers Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction,...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Sep 16, 2022
• Employees: 6
• Stock Exchange: NASDAQ
• Ticker Symbol: NXL
• Website: https://www.nexalin.com

Financial Performance

In 2024, Nexalin Technology's revenue was $168,721, an increase of 52.35% compared to the previous year's $110,748. Losses were -$7.61 million, 63.6% more than in 2023.

Analyst Summary

According to one analyst, the rating for NXL stock is "Strong Buy" and the 12-month stock price target is $5.0.

Price Target

$5.0

(420.78% upside)

Analyst Consensus: Strong Buy